title: Diagnosis and Management of Multiple Sclerosis in Children.
abstract: Growing evidence indicates the safety and well toleration of treatment by Disease-modifying in children suffering multiple sclerosis (MS). The treatment is not straight forward in a great number of patients, thus patients with pediatric MS must be managed by experienced specialized centers. Common treatments of multiple sclerosis for adults are first-line therapies. These therapies (firstline) are safe for children. Failure in treatment that leads to therapy alteration is almost prevalent in pediatric MS. Toleration against current second-line therapies has been shown in multiple sclerosis children. Oral agents have not been assessed in children MS patients. Although clinical trials in children are insufficient, immunomodulating managed children, experience a side effect similar to the adult MS patients. However, further prospective clinical studies, with large sample size and long follow-up are needed to distinguish the benefits and probable side effects of pediatric MS therapies.
authors.affiliation: Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran ; Isfahan Neurosciences Research Centre (INRC), Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Najafi
authors.affiliation: Medical student, Isfahan University of Medical Sciences, Faculty of Medicine, Isfahan, Iran ; Isfahan Neurosciences Research Centre (INRC), Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mohammad Amin
authors.initials: MA
authors.lastname: Najafi
authors.affiliation: Medical student, Isfahan University of Medical Sciences, Faculty of Medicine, Isfahan, Iran.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Nasr
keywords: Disease-modifying therapies; Multiple sclerosis; Pediatric MS; Treatment